Treatment with epigenetic inhibitors in combination with STEAP1 CAR T cell therapy could simultaneously enhance tumor STEAP1 expression and reprogram CAR T cells to favorable exhaustion-resistant differentiation states74,75, thereby mitigating tumor antigen loss and enhancing antitumor efficacy in prostate cancer. The gene discussed is LINC01194; the disease is neoplasm.